Skip to main content
Patient and carer information
Health professional information

ASCIA News

  • NBA SCIg Report
    On 17 March 2022, the National Blood Authority (NBA) engaged HealthConsult to develop a Report about uptake of subcutaneous immunoglobulin (SCIg).  The final report  "Evaluate and Develop Options to Improve Access to Subcutaneous Immunoglobulin (SCIg)" is now available on the...
  • PBAC Meeting March 2024  
    Consultation has opened for the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. This includes submissions for new or updated Pharmaceutical Benefits Scheme (PBS) listings of products that are relevant to allergy and immunology, as listed below...
  • Edible Insect Food Allergy Survey
    Healthcare workers are invited to participate in a short survey (~5 minutes) on reporting cases of edible insect food allergy after consumption of insect-based food products such as crickets, mealworms. green ants and witchetty grubs (native to Australia). This survey is...
  • Red Imported Fire Ants in Australia - Senate Inquiry
    There is currently a call for submissions to a Senate Inquiry for the potential impacts of Red Imported Fire Ants (RIFA) on the health of Australians, as well as costs. - see...
  • Updated Guidelines for Anaphylaxis Prevention and Management
    The National Allergy Council has updated the Best Practice Guidelines for anaphylaxis prevention and management in schools and children’s education/care services, which are now available on the re-designed Allergy Aware website – www.allergyaware.org.au The key changes to...
  • Updated ASCIA Dietary Avoidance for Food Allergy FAQ 
    ASCIA Dietary Avoidance for Food Allergy Frequently Asked Questions (FAQ) has been updated in December 2023 to include a QR code which links to short, easy to understand videos about how to read and understand food labels for food allergy. These vidoes are on the National...
  • ATAGI COVID-19 vaccine recommendations 2023
    Monovalent COVID-19 Omicron XBB.1.5 vaccines are now available in Australia, following the Therapeutic Goods Administration of Australia (TGA) approval of the following XBB 1.5 vaccines for use as primary and additional doses: Pfizer monovalent Omicron XBB.1.5 vaccine 5 -...
  • ASCIA Update – Shared Care Project
    ASCIA’s involvement in the National Allergy Council Shared Care project includes: Advocacy to increase access to care, including food and drug challenges, to improve diagnosis and management of allergic conditions. Education, training and mentorship of health...
More ASCIA News
ASCIA Member Login
Site last updated: 1 DEC 2023
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...